Only a handful of places left for our September 2026 cohort. Applications close soonApply now →

MSTA
Your future
starts here.

Oxygen facial

Also known as: oxygen infusion facial, oxygenating facial

An oxygen facial is a cosmetic facial treatment offered to improve the skin's appearance using oxygen-related products or equipment. Some systems apply oxygen with skincare, some release oxygen chemically, and others generate carbon dioxide at the skin surface.

In plain English — Oxygen facials are a family of treatments using different products and machines. Small studies of particular systems have reported changes in skin appearance or skin oxygen measurements. Choosing one means checking the exact treatment, its ingredients and whether it suits your skin.

Evidence status

Emerging

System-specific early clinical evidence. Small human studies report cosmetic changes, acne outcomes or short-term oxygen measurements for different systems. Their interventions and outcomes are not interchangeable, and independent confirmation of durable cosmetic benefit remains limited.

What an oxygen facial is, and the forms encountered#

An oxygen facial is a service category rather than one standardised intervention. The term usually identifies a facial offered for hydration, texture or a fresher-looking appearance, using oxygen-related equipment or products. The treatment components determine what the client actually receives.[1, 2, 3]i

Three examples illustrate the range:

  • Applicator-delivered oxygen with skincare: Intraceuticals describes oxygen delivery alongside its proprietary preparations. This is the manufacturer’s account of its system.[1, 3, 5]i
  • Chemical oxygen release:Circadia’s Oxygen Rx training material describes magnesium peroxide, a water-containing gel and an enzyme activator. Its brand-specific account sits in Circadia.[2, 3]i
  • CO2-generating surface treatment: OxyGeneo uses a capsule and gel that produce carbon dioxide while the applicator exfoliates the surface. The 2017 cosmetic study also included an RF stage and massage.[3, 5]

Use of oxygen facials in aesthetic practice#

These treatments are offered as cosmetic facial services, with the aim of improving how skin looks and feels. The consultation should identify the client’s actual concern—dry-feeling skin, texture, visible lines or blemishes—and then the exact system and products proposed. Commercial descriptions explain intended uses; the human evidence below concerns specified interventions.[1, 3, 5]i

A combined service may include exfoliation, topical skincare or radiofrequency, each requiring its own assessment. Record these components rather than documenting only “oxygen facial”. Medical management of acne or rosacea belongs in the relevant clinical pathway; neither an operating protocol nor prescribing advice is provided here.[9, 10]i

Contraindications and cautions#

Known allergy to an ingredient excludes that preparation. Review the whole product combination, not only the gas or the step that gives the service its name. Allergy and intolerance were exclusion criteria in the clinical reports.[3, 4, 5]i

Active inflammation, a skin lesion requiring diagnosis, recent resurfacing or other procedures, and any additional energy-based component require a treatment-specific decision before proceeding. The cosmetic studies excluded active skin disease, pregnancy or lactation and various recent interventions. Those exclusions describe who was not studied; they are not proof of pregnancy harm or a universal list for every oxygen-related facial. Follow the actual system’s instructions and any relevant clinician advice.[3, 5]i

For systems using oxygen gas, include oxygen enrichment, ignition sources, equipment condition, compatible components and ventilation in the risk assessment. HSE’s cited guidance is for Great Britain workplaces using oxygen cylinders. A chemically activated mask is not a cylinder system and should be assessed for its own ingredients and instructions.[7]i

Clinical uses and the evidence behind them#

Cosmetic appearance

A 2017 uncontrolled study treated ten women aged 27–61 on the face over approximately two months. The intervention combined OxyGeneo exfoliation and topical gel with radiofrequency and massage. Investigators and participants reported improvements in appearance and satisfaction. This was a complete combined service, not an isolated test of oxygen. The authors reported no funding or relevant conflicts. Actual phototype distribution was not given.[3]

Acne-related research

A 2018 paper reported a 20-adult mild-acne comparison over 16 weeks, followed for another eight weeks. Participants received either X2 Exea oxygen alone or oxygen plus a multicomponent topical preparation. Both groups improved, with greater improvement reported for the combination. Both received oxygen, so the comparison does not determine how much benefit oxygen added. The authors reported no funding or conflicts; the treated site and per-arm numbers were not clearly specified. This medical study is not a generic facial protocol.[4]i

Skin oxygen measurements

A randomised split-face study in 12 healthy adults aged 23–64 compared a CO2-generating OxyGeneo treatment with particle-free microdermabrasion. The immediate increase in transcutaneous oxygen tension was greater after the CO2 treatment, using a one-sided paired analysis. This is a measured physiological finding; its duration and cosmetic significance were not determined. The authors declared no conflicts, but no separate funding statement was found in the retrieved original proof.[5]

Selecting a treatment and setting expectations#

Start by naming the system, the preparations and any exfoliating or energy-based additions. Match the cosmetic aim to evidence for that intervention: an appearance study, an acne comparison and an oxygen measurement answer different questions. Explain the intended outcome in those terms.[3, 5]i

Current skin condition, known product reactions and recent procedures help determine whether to proceed, defer or refer. A client already under care for a skin condition should have cosmetic treatment considered in that context, rather than replacing the existing management plan.[9, 10]i

Adverse effects and their management#

In the ten-person combination study, all participants described minimal or no overall pain, with a slightly abrasive or tingling exfoliation stage. The separate 12-person CO2 study describes temporary redness and discomfort and reports no severe or permanent adverse effects among its participants. These are observations in small selected samples, not estimates of uncommon reaction rates.[3, 5]i

Unexpected persistent burning, marked inflammation or skin injury is a reason to stop and arrange appropriate assessment. Record the products and each treatment component so a subsequent review can identify the possible cause. Do not continue exposure simply to complete the service.[3, 5]i

Equipment-related oxygen leaks or suspected enrichment require the relevant gas-safety response. Maintain the equipment, keep ignition sources away and follow the supplier’s instructions and workplace risk assessment. This is an equipment issue distinct from a reaction to a serum or mask.[7]i

Referral and scope boundaries#

Acne with uncertain diagnosis, nodules or cysts, scarring, persistent pigmentation or substantial distress needs the appropriate medical pathway. The acne vulgaris entry covers that assessment.[9, 10]i

Persistent facial redness and associated papules, pustules or eye symptoms should be assessed in the context of rosacea, rather than assumed to be a cosmetic oxygen deficiency. Rosacea care is individualised; ocular symptoms may require eye assessment. Guideline-supported management should remain the basis of care.[9, 10]i

Mechanism of action#

Oxygen participates in skin physiology, and atmospheric oxygen can contribute to superficial skin oxygen supply. A physiological study measured oxygen uptake on normal humidified volar-forearm skin in 20 volunteers. It examined acute flux and an experimental interruption of blood flow, not a facial treatment. Only the original abstract was retrievable, so its funding and conflict declarations could not be checked.[6]

Applicator systems deliver oxygen at the surface alongside skincare; chemical-release systems use their own formulation chemistry. The Circadia presentation describes the components of Oxygen Rx, while Intraceuticals describes its applicator approach. These descriptions explain the respective designs rather than supplying independent efficacy estimates.[1, 2, 3]i

For the CO2-generating approach, citric acid and bicarbonate chemistry produces surface carbon dioxide. The proposed oxygenation mechanism involves CO2-facilitated unloading of oxygen from haemoglobin—the Bohr effect. The small split-face study measured an associated short-term rise in skin oxygen tension.[3, 5]

Commonly misstated claims#

“It works like a medical hyperbaric oxygen chamber”

Claim heard: evidence for hyperbaric oxygen therapy establishes the benefits of a cosmetic oxygen facial.

Literature finding: HBOT involves breathing oxygen within a chamber at increased pressure. A topical applicator or chemical surface treatment is a different exposure. The FDA source cited here defines chamber treatment; it does not evaluate these facials.[1, 2, 8]i

Supported statement: assess a facial using evidence for its own delivery system and outcome, not by borrowing the results of medical chamber treatment.[1, 2, 8]i

“A rise in oxygen proves that the facial builds collagen”

Claim heard: a measured increase in oxygen tension establishes dermal collagen production and lasting rejuvenation.

Literature finding:the 2015 study measured a short-term physiological endpoint. The 2017 appearance study combined several steps, including radiofrequency, without isolating oxygen’s contribution.[3, 5]i

Supported statement: oxygen measurement and cosmetic appearance are separate findings; these studies do not establish that an isolated oxygen step builds new collagen.[3, 5]i

“Oxygen Rx has established clinical evidence for rosacea”

Claim heard:the named treatment’s proposed vascular and antimicrobial effects establish a rosacea benefit. Circadia’s training presentation puts forward these rationales.[2, 3]i

Literature finding: no controlled human rosacea trial of the named Oxygen Rx treatment was located in the targeted search completed on 16 September 2026.[no source found]

Supported statement: its controlled clinical rosacea benefit remains unverified in this search. The Circadiaentry examines the manufacturer’s rationale in more detail.

Areas of remaining uncertainty#

  • Duration of cosmetic change: the appearance study and immediate physiological experiment do not establish a dependable duration of benefit. Avoid promising a maintenance interval on their basis.[5]
  • Applicability across skin tones: broad eligibility is not the same as reporting the enrolled phototypes. Discuss outcomes for under-represented clients without assuming that every group has been adequately studied.[3]

Frequently asked questions#

Are all oxygen facials the same?

No. Ask whether the service applies oxygen gas, releases oxygen chemically or generates CO2 at the surface, and which skincare or additional equipment is included. These differences determine the relevant evidence and precautions.[1, 2, 3]i

Is pregnancy an automatic yes because the treatment is non-injectable?

Pregnancy and lactation were excluded from the cosmetic studies discussed here. Those trials therefore cannot establish safety in these groups; the exact products, equipment instructions and relevant clinical advice should govern the decision.[3, 5]i

What should a client expect?

The treatment is offered for cosmetic appearance and feel. Small system-specific studies have reported improvements, so describe the intended aim while keeping expectations tied to the actual combination being used.[1, 3, 5]i

References#

Each source is graded by evidence tier. Tier 4 material (manufacturer documents, expert consensus, practitioner experience) is useful for protocol and context, and is never presented as equivalent to independent clinical evidence.

  1. Intraceuticals. Oxygen Facial. Undated. Accessed 16 September 2026.Tier 4Supports: Original manufacturer page describing applicator-delivered oxygen with proprietary skincare and cosmetic hydration/appearance aims; claims are attributed to the manufacturer, not treated as independent clinical findings.Funding / interest: Manufacturer-owned commercial description of its own treatments and products.
  2. Circadia. Oxygen Rx Treatment and SWiCH Dermal Rejuvenation System training presentation. 2020. Oxygen Rx slides, pp. 1–3.Tier 4Supports: Original branded presentation; Oxygen Rx magnesium-peroxide, water-gel and enzyme-activator description and manufacturer's rosacea claims. The separate SWiCH product's contraindications are not transferred to Oxygen Rx.Funding / interest: Manufacturer-authored training material with direct commercial interest; no independent trial or quantitative oxygen-delivery data in the presentation.
  3. Diaz D, Boonsiri M, Okawa J, Dekranes D, Ditre CM. Oxygeneo—A Unique Three-in-one Treatment of Exfoliation, Infusion, and Oxygenation via the Bohr Effect and TriPollar Radiofrequency for Skin Rejuvenation. J Clin Aesthet Dermatol. 2017;10(11):22–25. PMID:29399257.Tier 3Supports: Original full article; uncontrolled facial study of ten women aged 27–61 over approximately two months. CO2-generating exfoliation plus selected topical gel, RF add-on and massage; appearance and satisfaction outcomes. Fitzpatrick I–VI was eligibility, not a reported distribution. Questionnaire denominator wording differs between methods and results, so no percentage-based benefit is used.Funding / interest: Authors report no funding and no relevant conflicts of interest. Commercial distributor hosts the original PDF; hosting does not establish sponsorship.
  4. Bennardo L, Del Duca E, Dastoli S, Schipani G, Scali E, Silvestri M, Nisticò SP. Potential applications of topical oxygen therapy in dermatology. Dermatol Pract Concept. 2018;8(4):272–276. doi:10.5826/dpc.0804a04. PMID:30479854.Tier 2Supports: Original full XML; mild-acne substudy reports random allocation of 20 adults to X2 Exea oxygen alone or oxygen plus a multicomponent topical preparation, 16 weeks with eight-week follow-up. Both arms received oxygen. Randomisation methods, arm denominators and treatment site are not clearly reported; age range conflicts with eligibility. Other uncontrolled disease series are not used as facial efficacy evidence.Funding / interest: Authors report no funding and no conflicts of interest.
  5. Seidel R, Moy R. Effect of Carbon Dioxide Facial Therapy on Skin Oxygenation. J Drugs Dermatol. 2015;14(9):976–980. PMID:26355616.Tier 2Supports: Complete original proof and original indexed abstract retrieved. Twelve healthy adults aged 23–64, randomised treatment order and facial side, OxyGeneo versus particle-free microdermabrasion; transcutaneous oxygen tension shortly after treatment. Final pagination verified against original indexed record; PDF proof uses provisional pages. No confidence interval supplied.Funding / interest: Authors declare no conflicts. No separate funding statement located in the retrieved proof; independence cannot be assumed from this omission.
  6. Stücker M, Struk A, Altmeyer P, Herde M, Baumgärtl H, Lübbers DW. The cutaneous uptake of atmospheric oxygen contributes significantly to the oxygen supply of human dermis and epidermis. J Physiol. 2002;538(Pt 3):985–994. doi:10.1113/jphysiol.2001.013067. PMID:11826181.Tier 3Supports: Original abstract; acute oxygen-flux measurements on normal humidified volar-forearm skin of 20 volunteers, with experimental blood-flow interruption. Physiological atmospheric-oxygen contribution, not a cosmetic facial trial. Full original text was inaccessible through attempted routes.Funding / interest: Funding and conflicts unavailable in the original abstract; no independence assumption.
  7. Health and Safety Executive. Oxygen use in the workplace: Fire and explosion hazards. INDG459. 2013.Tier 1Supports: Original GB occupational guidance addressed to oxygen-cylinder users; oxygen enrichment, fire, compatible equipment, maintenance and ventilation. Not a clinical safety trial or four-nation cosmetic licensing rule. Cylinder/pressure hazards are not attributed to chemical masks.Funding / interest: Public HSE occupational safety guidance; no commercial sponsorship identified.
  8. US Food and Drug Administration. Follow Instructions for Safe Use of Hyperbaric Oxygen Therapy Devices—Letter to Health Care Providers. 25 August 2025.Tier 1Supports: Original FDA definition of HBOT as breathing oxygen in a pressurised chamber. Used to distinguish exposure, not to transfer US regulatory classifications or reported chamber injuries to salon facials.Funding / interest: US public regulator communication; no commercial sponsorship identified.
  9. National Institute for Health and Care Excellence. Acne vulgaris: management. NG198. Updated 3 August 2026. Recommendations 1.4.Tier 1Supports: Original current NICE HTML; referral for diagnostic uncertainty, nodulocystic acne, scarring, persistent pigmentary changes and psychological distress. No prescribing algorithm or operator licensing claim is reproduced.Funding / interest: Publicly developed NICE guideline with committee interests managed through NICE's process.
  10. Hampton PJ, Berth-Jones J, Duarte Williamson CE, et al. British Association of Dermatologists guidelines for the management of people with rosacea 2021. Br J Dermatol. 2021;185(4):725–735. doi:10.1111/bjd.20485.Tier 1Supports: Original complete guideline; individualised rosacea management, supportive skincare and ocular referral. Its absence of an Oxygen Rx recommendation is not used as proof of ineffectiveness.Funding / interest: Guideline reports no funding. Author disclosures include PJH research or educational/travel relationships with LEO, Janssen, UCB and Eli Lilly; CEDW speaking for AbbVie, Galderma and Janssen; TAL advisory work for Galderma, La Roche-Posay and Novartis and Novartis speaking; DS Galderma conference travel. JBJ previously ran a rosacea clinical-trial unit.